ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) fell 6% during trading on Monday . The stock traded as low as $3.68 and last traded at $3.77. 873,196 shares were traded during trading, a decline of 82% from the average session volume of 4,945,083 shares. The stock had previously closed at $4.01.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler reduced their price target on ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a research report on Monday.
Read Our Latest Stock Analysis on IBRX
ImmunityBio Price Performance
The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of -3.67 and a beta of 1.07. The stock has a 50-day moving average price of $5.67 and a 200-day moving average price of $5.80.
Institutional Trading of ImmunityBio
A number of hedge funds have recently made changes to their positions in the business. Meridian Management Co. acquired a new stake in ImmunityBio during the 4th quarter worth approximately $46,000. Tower Research Capital LLC TRC increased its stake in ImmunityBio by 43.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company's stock worth $47,000 after acquiring an additional 2,844 shares during the period. Private Advisor Group LLC bought a new position in ImmunityBio during the 4th quarter worth $53,000. Simplicity Wealth LLC bought a new position in ImmunityBio during the 1st quarter worth $58,000. Finally, Bleakley Financial Group LLC bought a new position in shares of ImmunityBio in the 1st quarter valued at $58,000. 8.58% of the stock is owned by institutional investors and hedge funds.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
